ID   NCOR1_HUMAN             Reviewed;        2440 AA.
AC   O75376; B3DLF8; E9PGV6; Q86YY0; Q9UPV5; Q9UQ18;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2004, sequence version 2.
DT   28-JUN-2023, entry version 229.
DE   RecName: Full=Nuclear receptor corepressor 1;
DE            Short=N-CoR;
DE            Short=N-CoR1;
GN   Name=NCOR1; Synonyms=KIAA1047;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=9724795; DOI=10.1073/pnas.95.18.10860;
RA   Wang J., Hoshino T., Redner R.L., Kajigaya S., Liu J.M.;
RT   "ETO, fusion partner in t(8;21) acute myeloid leukemia, represses
RT   transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10860-10865(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Yu L.;
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10470851; DOI=10.1093/dnares/6.3.197;
RA   Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N., Tanaka A.,
RA   Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIV. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:197-205(1999).
RN   [4]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 974-2440 (ISOFORM 1).
RX   PubMed=10444336; DOI=10.1006/geno.1998.5694;
RA   Nagaya T., Chen K.-S., Fujieda M., Ohmori S., Richer J.K., Horwitz K.B.,
RA   Lupski J.R., Seo H.;
RT   "Localization of the human nuclear receptor co-repressor (hN-CoR) gene
RT   between the CMT1A and the SMS critical regions of chromosome 17p11.2.";
RL   Genomics 59:339-341(1999).
RN   [9]
RP   INTERACTION WITH RORA.
RX   PubMed=9328355; DOI=10.1210/mend.11.11.0002;
RA   Harding H.P., Atkins G.B., Jaffe A.B., Seo W.J., Lazar M.A.;
RT   "Transcriptional activation and repression by RORalpha, an orphan nuclear
RT   receptor required for cerebellar development.";
RL   Mol. Endocrinol. 11:1737-1746(1997).
RN   [10]
RP   INTERACTION WITH TRIM28.
RX   PubMed=11013263; DOI=10.1074/jbc.m007864200;
RA   Underhill C., Qutob M.S., Yee S.P., Torchia J.;
RT   "A novel nuclear receptor corepressor complex, N-CoR, contains components
RT   of the mammalian SWI/SNF complex and the corepressor KAP-1.";
RL   J. Biol. Chem. 275:40463-40470(2000).
RN   [11]
RP   INTERACTION WITH CBFA2T3.
RX   PubMed=11533236; DOI=10.1128/mcb.21.19.6470-6483.2001;
RA   Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N.,
RA   Downing J.R., Meyers S., Hiebert S.W.;
RT   "ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with
RT   multiple histone deacetylases and binds mSin3A through its oligomerization
RT   domain.";
RL   Mol. Cell. Biol. 21:6470-6483(2001).
RN   [12]
RP   COMPONENT OF THE N-COR COMPLEX WITH TBL1X; TBL1R; NCOR2; GPS2 AND HDAC3.
RX   PubMed=11931768; DOI=10.1016/s1097-2765(02)00468-9;
RA   Zhang J., Kalkum M., Chait B.T., Roeder R.G.;
RT   "The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK
RT   pathway through the integral subunit GPS2.";
RL   Mol. Cell 9:611-623(2002).
RN   [13]
RP   INTERACTION WITH HDAC9.
RX   PubMed=12590135; DOI=10.1074/jbc.m212935200;
RA   Petrie K., Guidez F., Howell L., Healy L., Waxman S., Greaves M.,
RA   Zelent A.;
RT   "The histone deacetylase 9 gene encodes multiple protein isoforms.";
RL   J. Biol. Chem. 278:16059-16072(2003).
RN   [14]
RP   INTERACTION WITH DACH1.
RX   PubMed=14525983; DOI=10.1074/jbc.m310021200;
RA   Wu K., Yang Y., Wang C., Davoli M.A., D'Amico M., Li A., Cveklova K.,
RA   Kozmik Z., Lisanti M.P., Russell R.G., Cvekl A., Pestell R.G.;
RT   "DACH1 inhibits transforming growth factor-beta signaling through binding
RT   Smad4.";
RL   J. Biol. Chem. 278:51673-51684(2003).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH CORO2A; GPS2; HDAC3; TBL1R; TBL1X AND
RP   ZBTB33.
RX   PubMed=14527417; DOI=10.1016/j.molcel.2003.08.008;
RA   Yoon H.-G., Chan D.W., Reynolds A.B., Qin J., Wong J.;
RT   "N-CoR mediates DNA methylation-dependent repression through a methyl CpG
RT   binding protein Kaiso.";
RL   Mol. Cell 12:723-734(2003).
RN   [16]
RP   INTERACTION WITH BCL6.
RX   PubMed=15454082; DOI=10.1016/j.cell.2004.09.014;
RA   Fujita N., Jaye D.L., Geigerman C., Akyildiz A., Mooney M.R., Boss J.M.,
RA   Wade P.A.;
RT   "MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte
RT   differentiation.";
RL   Cell 119:75-86(2004).
RN   [17]
RP   INTERACTION WITH KDM3A.
RX   PubMed=16024779; DOI=10.1128/mcb.25.15.6404-6414.2005;
RA   Zhang D., Yoon H.-G., Wong J.;
RT   "JMJD2A is a novel N-CoR-interacting protein and is involved in repression
RT   of the human transcription factor achaete scute-like homologue 2
RT   (ASCL2/Hash2).";
RL   Mol. Cell. Biol. 25:6404-6414(2005).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-224; SER-999 AND SER-2151,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2184, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [20]
RP   INTERACTION WITH HEXIM1.
RX   PubMed=17452463; DOI=10.1128/mcb.00857-06;
RA   Fu J., Yoon H.-G., Qin J., Wong J.;
RT   "Regulation of P-TEFb elongation complex activity by CDK9 acetylation.";
RL   Mol. Cell. Biol. 27:4641-4651(2007).
RN   [21]
RP   INTERACTION WITH BAZ1A.
RX   PubMed=17519354; DOI=10.1210/me.2007-0095;
RA   Ewing A.K., Attner M., Chakravarti D.;
RT   "Novel regulatory role for human Acf1 in transcriptional repression of
RT   vitamin D3 receptor-regulated genes.";
RL   Mol. Endocrinol. 21:1791-1806(2007).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1472, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1472, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1111; SER-1472; SER-1977;
RP   SER-1981; SER-2184; THR-2399; SER-2436 AND SER-2438, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1472; SER-1977; SER-2151;
RP   SER-2184 AND SER-2436, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1412, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1472; SER-2184 AND SER-2438,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   FUNCTION, AND INTERACTION WITH AR AND ZBTB7A.
RX   PubMed=20812024; DOI=10.1007/s00018-010-0511-7;
RA   Cui J., Yang Y., Zhang C., Hu P., Kan W., Bai X., Liu X., Song H.;
RT   "FBI-1 functions as a novel AR co-repressor in prostate cancer cells.";
RL   Cell. Mol. Life Sci. 68:1091-1103(2011).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1195; SER-1472; SER-2151;
RP   SER-2436 AND SER-2438, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [32]
RP   INTERACTION WITH BCL6.
RX   PubMed=23911289; DOI=10.1016/j.celrep.2013.06.016;
RA   Hatzi K., Jiang Y., Huang C., Garrett-Bakelman F., Gearhart M.D.,
RA   Giannopoulou E.G., Zumbo P., Kirouac K., Bhaskara S., Polo J.M.,
RA   Kormaksson M., Mackerell A.D. Jr., Xue F., Mason C.E., Hiebert S.W.,
RA   Prive G.G., Cerchietti L., Bardwell V.J., Elemento O., Melnick A.;
RT   "A hybrid mechanism of action for BCL6 in B cells defined by formation of
RT   functionally distinct complexes at enhancers and promoters.";
RL   Cell Rep. 4:578-588(2013).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-172; SER-224; SER-1111;
RP   SER-1196; SER-1249; SER-1263; SER-1281; SER-1322; SER-1450; SER-1472;
RP   SER-1592; SER-1977; SER-2120; SER-2151 AND SER-2184, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [34]
RP   INTERACTION WITH DEAF1.
RX   PubMed=23372760; DOI=10.1371/journal.pone.0054715;
RA   Kateb F., Perrin H., Tripsianes K., Zou P., Spadaccini R., Bottomley M.,
RA   Franzmann T.M., Buchner J., Ansieau S., Sattler M.;
RT   "Structural and functional analysis of the DEAF-1 and BS69 MYND domains.";
RL   PLoS ONE 8:E54715-E54715(2013).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-224; SER-1472; SER-2136 AND
RP   SER-2151, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1106, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [37]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1106, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [38]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1106, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [39]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1106; LYS-1184; LYS-1389;
RP   LYS-1412 AND LYS-1518, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [40]
RP   INTERACTION WITH VDR.
RX   PubMed=28698609; DOI=10.1038/s41598-017-05081-x;
RA   Tamura M., Ishizawa M., Isojima T., Oezen S., Oka A., Makishima M.,
RA   Kitanaka S.;
RT   "Functional analyses of a novel missense and other mutations of the vitamin
RT   D receptor in association with alopecia.";
RL   Sci. Rep. 7:5102-5102(2017).
RN   [41]
RP   STRUCTURE BY NMR OF 433-486.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first SANT domain from human nuclear receptor
RT   corepressor 1.";
RL   Submitted (APR-2008) to the PDB data bank.
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 2047-2065 IN COMPLEX WITH RARA AND
RP   RARA AGONIST BMS493, AND INTERACTION WITH RARA.
RX   PubMed=20543827; DOI=10.1038/nsmb.1855;
RA   le Maire A., Teyssier C., Erb C., Grimaldi M., Alvarez S., de Lera A.R.,
RA   Balaguer P., Gronemeyer H., Royer C.A., Germain P., Bourguet W.;
RT   "A unique secondary-structure switch controls constitutive gene repression
RT   by retinoic acid receptor.";
RL   Nat. Struct. Mol. Biol. 17:801-807(2010).
CC   -!- FUNCTION: Mediates transcriptional repression by certain nuclear
CC       receptors (PubMed:20812024). Part of a complex which promotes histone
CC       deacetylation and the formation of repressive chromatin structures
CC       which may impede the access of basal transcription factors.
CC       Participates in the transcriptional repressor activity produced by
CC       BCL6. Recruited by ZBTB7A to the androgen response elements/ARE on
CC       target genes, negatively regulates androgen receptor signaling and
CC       androgen-induced cell proliferation (PubMed:20812024). Mediates the
CC       NR1D1-dependent repression and circadian regulation of TSHB expression
CC       (By similarity). The NCOR1-HDAC3 complex regulates the circadian
CC       expression of the core clock gene ARTNL/BMAL1 and the genes involved in
CC       lipid metabolism in the liver (By similarity).
CC       {ECO:0000250|UniProtKB:Q60974, ECO:0000269|PubMed:14527417,
CC       ECO:0000269|PubMed:20812024}.
CC   -!- SUBUNIT: Forms a large corepressor complex that contains SIN3A/B and
CC       histone deacetylases HDAC1 and HDAC2. This complex associates with the
CC       thyroid receptor (TR) and the retinoid acid receptor (RAR) in the
CC       absence of ligand. Interacts directly with RARA; the interaction is
CC       facilitated with RARA trimethylation. Component of the N-Cor repressor
CC       complex, at least composed of CBFA2T3, HEXIM1, NCOR1, NCOR2, HDAC3,
CC       TBL1X, TBL1XR1, CORO2A and GPS2. Interacts with ZBTB33; the interaction
CC       serves to recruit the N-CoR complex to promoter regions containing
CC       methylated CpG dinucleotides. Interacts with TRIM28 and KDM3A.
CC       Interacts (via the RD1 domain) with BAZ1A (via its N-terminal); the
CC       interaction corepresses a number of NCOR1-regulated genes. Interacts
CC       with BCL6, C1D, DACH1, HEXIM1, HDAC7, RORA, RORC, SAP30, SIAH2, SIN3A
CC       and SIN3B. May interact with DEAF1. Interacts with RXRA. Interacts with
CC       SETD5 (By similarity). Interacts with VDR (PubMed:28698609). Interacts
CC       with ZBTB7A (PubMed:20812024). Interacts with AR (PubMed:20812024).
CC       Interacts with HDAC3 (By similarity). {ECO:0000250|UniProtKB:Q60974,
CC       ECO:0000269|PubMed:11013263, ECO:0000269|PubMed:11533236,
CC       ECO:0000269|PubMed:12590135, ECO:0000269|PubMed:14525983,
CC       ECO:0000269|PubMed:14527417, ECO:0000269|PubMed:15454082,
CC       ECO:0000269|PubMed:16024779, ECO:0000269|PubMed:17452463,
CC       ECO:0000269|PubMed:17519354, ECO:0000269|PubMed:20543827,
CC       ECO:0000269|PubMed:20812024, ECO:0000269|PubMed:23372760,
CC       ECO:0000269|PubMed:23911289, ECO:0000269|PubMed:28698609,
CC       ECO:0000269|PubMed:9328355}.
CC   -!- INTERACTION:
CC       O75376; Q9UI36: DACH1; NbExp=2; IntAct=EBI-347233, EBI-347111;
CC       O75376; O15379: HDAC3; NbExp=5; IntAct=EBI-347233, EBI-607682;
CC       O75376; Q9UJC3: HOOK1; NbExp=3; IntAct=EBI-347233, EBI-746704;
CC       O75376; P42858: HTT; NbExp=3; IntAct=EBI-347233, EBI-466029;
CC       O75376; O00629: KPNA4; NbExp=4; IntAct=EBI-347233, EBI-396343;
CC       O75376; I6L9F6: NEFL; NbExp=3; IntAct=EBI-347233, EBI-10178578;
CC       O75376; P20393: NR1D1; NbExp=3; IntAct=EBI-347233, EBI-2811738;
CC       O75376; P55055: NR1H2; NbExp=6; IntAct=EBI-347233, EBI-745354;
CC       O75376; Q13133: NR1H3; NbExp=2; IntAct=EBI-347233, EBI-781356;
CC       O75376; Q07869: PPARA; NbExp=3; IntAct=EBI-347233, EBI-78615;
CC       O75376; P37231: PPARG; NbExp=2; IntAct=EBI-347233, EBI-781384;
CC       O75376; P62937: PPIA; NbExp=3; IntAct=EBI-347233, EBI-437708;
CC       O75376; P10276: RARA; NbExp=6; IntAct=EBI-347233, EBI-413374;
CC       O75376; Q06455: RUNX1T1; NbExp=5; IntAct=EBI-347233, EBI-743342;
CC       O75376; Q99719: SEPTIN5; NbExp=3; IntAct=EBI-347233, EBI-373345;
CC       O75376; Q8IUQ4-2: SIAH1; NbExp=3; IntAct=EBI-347233, EBI-11522811;
CC       O75376; P12755: SKI; NbExp=4; IntAct=EBI-347233, EBI-347281;
CC       O75376; P61764: STXBP1; NbExp=3; IntAct=EBI-347233, EBI-960169;
CC       O75376; Q13263: TRIM28; NbExp=4; IntAct=EBI-347233, EBI-78139;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00624}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O75376-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75376-2; Sequence=VSP_010207, VSP_010208;
CC       Name=3; Synonyms=b;
CC         IsoId=O75376-3; Sequence=VSP_046468, VSP_010207, VSP_046469,
CC                                  VSP_046470;
CC   -!- DOMAIN: The N-terminal region contains three independent domains that
CC       are capable of mediating transcriptional repression (RD1, RD2 and RD3).
CC   -!- DOMAIN: The C-terminal region contains two separate nuclear receptor-
CC       interacting domains (ID1 and ID2), each of which contains a conserved
CC       sequence referred to as the CORNR box. This motif is necessary and
CC       sufficient for binding to unligated nuclear hormone receptors, while
CC       sequences flanking the CORNR box determine the precise nuclear hormone
CC       receptor specificity (By similarity). {ECO:0000250}.
CC   -!- PTM: Ubiquitinated; mediated by SIAH2 and leading to its subsequent
CC       proteasomal degradation. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the N-CoR nuclear receptor corepressors family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA82999.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF044209; AAC33550.1; -; mRNA.
DR   EMBL; AF303586; AAO32942.1; -; mRNA.
DR   EMBL; AB028970; BAA82999.2; ALT_INIT; mRNA.
DR   EMBL; AC002553; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005971; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471222; EAX04494.1; -; Genomic_DNA.
DR   EMBL; BC167431; AAI67431.1; -; mRNA.
DR   EMBL; AB019524; BAA75814.1; -; mRNA.
DR   CCDS; CCDS11175.1; -. [O75376-1]
DR   CCDS; CCDS54094.1; -. [O75376-3]
DR   CCDS; CCDS54095.1; -. [O75376-2]
DR   RefSeq; NP_001177367.1; NM_001190438.1. [O75376-3]
DR   RefSeq; NP_001177369.1; NM_001190440.1. [O75376-2]
DR   RefSeq; NP_006302.2; NM_006311.3. [O75376-1]
DR   RefSeq; XP_011522388.1; XM_011524086.2. [O75376-2]
DR   PDB; 2EQR; NMR; -; A=433-486.
DR   PDB; 3H52; X-ray; 2.80 A; M/N=2258-2276.
DR   PDB; 3KMZ; X-ray; 2.10 A; C/D=2047-2065.
DR   PDB; 3N00; X-ray; 2.60 A; B=2045-2065.
DR   PDB; 4MDD; X-ray; 2.40 A; C/D=2260-2274.
DR   PDB; 4WVD; X-ray; 2.90 A; C/D=2259-2275.
DR   PDB; 6ONI; X-ray; 1.80 A; D=2256-2278.
DR   PDB; 6WMQ; X-ray; 2.55 A; E/F=2044-2066.
DR   PDB; 6WMS; X-ray; 2.00 A; E/F=2256-2278.
DR   PDB; 6XXS; X-ray; 3.25 A; C/D/G/H=1340-1356.
DR   PDB; 6XYX; X-ray; 1.44 A; C/D=1340-1356.
DR   PDB; 6XZZ; X-ray; 1.39 A; B=1726-1742.
DR   PDB; 6Y17; X-ray; 1.56 A; A/B=1733-1741, C/D=1340-1356.
DR   PDB; 6ZBU; X-ray; 2.46 A; A/B/E/F/I/J=1733-1741, C/D/G/H/K/L=1340-1356.
DR   PDB; 8D8I; X-ray; 2.50 A; B=2045-2064.
DR   PDB; 8DKN; X-ray; 1.95 A; C=2260-2272.
DR   PDB; 8DKV; X-ray; 1.59 A; C=2259-2272.
DR   PDBsum; 2EQR; -.
DR   PDBsum; 3H52; -.
DR   PDBsum; 3KMZ; -.
DR   PDBsum; 3N00; -.
DR   PDBsum; 4MDD; -.
DR   PDBsum; 4WVD; -.
DR   PDBsum; 6ONI; -.
DR   PDBsum; 6WMQ; -.
DR   PDBsum; 6WMS; -.
DR   PDBsum; 6XXS; -.
DR   PDBsum; 6XYX; -.
DR   PDBsum; 6XZZ; -.
DR   PDBsum; 6Y17; -.
DR   PDBsum; 6ZBU; -.
DR   PDBsum; 8D8I; -.
DR   PDBsum; 8DKN; -.
DR   PDBsum; 8DKV; -.
DR   AlphaFoldDB; O75376; -.
DR   SMR; O75376; -.
DR   BioGRID; 114973; 309.
DR   CORUM; O75376; -.
DR   DIP; DIP-29402N; -.
DR   ELM; O75376; -.
DR   IntAct; O75376; 131.
DR   MINT; O75376; -.
DR   STRING; 9606.ENSP00000268712; -.
DR   BindingDB; O75376; -.
DR   ChEMBL; CHEMBL3038484; -.
DR   DrugCentral; O75376; -.
DR   CarbonylDB; O75376; -.
DR   GlyConnect; 2903; 1 O-GlcNAc glycan (1 site).
DR   GlyCosmos; O75376; 35 sites, 2 glycans.
DR   GlyGen; O75376; 77 sites, 2 O-linked glycans (77 sites).
DR   iPTMnet; O75376; -.
DR   MetOSite; O75376; -.
DR   PhosphoSitePlus; O75376; -.
DR   SwissPalm; O75376; -.
DR   BioMuta; NCOR1; -.
DR   EPD; O75376; -.
DR   jPOST; O75376; -.
DR   MassIVE; O75376; -.
DR   MaxQB; O75376; -.
DR   PaxDb; O75376; -.
DR   PeptideAtlas; O75376; -.
DR   ProteomicsDB; 20402; -.
DR   ProteomicsDB; 49948; -. [O75376-1]
DR   ProteomicsDB; 49949; -. [O75376-2]
DR   Antibodypedia; 13188; 471 antibodies from 37 providers.
DR   CPTC; O75376; 3 antibodies.
DR   DNASU; 9611; -.
DR   Ensembl; ENST00000268712.8; ENSP00000268712.2; ENSG00000141027.23. [O75376-1]
DR   Ensembl; ENST00000395848.5; ENSP00000379189.1; ENSG00000141027.23. [O75376-3]
DR   Ensembl; ENST00000395851.5; ENSP00000379192.1; ENSG00000141027.23. [O75376-2]
DR   GeneID; 9611; -.
DR   KEGG; hsa:9611; -.
DR   MANE-Select; ENST00000268712.8; ENSP00000268712.2; NM_006311.4; NP_006302.2.
DR   UCSC; uc002gpn.4; human. [O75376-1]
DR   AGR; HGNC:7672; -.
DR   CTD; 9611; -.
DR   DisGeNET; 9611; -.
DR   GeneCards; NCOR1; -.
DR   HGNC; HGNC:7672; NCOR1.
DR   HPA; ENSG00000141027; Low tissue specificity.
DR   MIM; 600849; gene.
DR   neXtProt; NX_O75376; -.
DR   OpenTargets; ENSG00000141027; -.
DR   PharmGKB; PA31477; -.
DR   VEuPathDB; HostDB:ENSG00000141027; -.
DR   eggNOG; KOG1878; Eukaryota.
DR   GeneTree; ENSGT00940000155093; -.
DR   HOGENOM; CLU_000922_0_0_1; -.
DR   InParanoid; O75376; -.
DR   OMA; AVIPPMX; -.
DR   OrthoDB; 5482374at2759; -.
DR   PhylomeDB; O75376; -.
DR   TreeFam; TF106423; -.
DR   PathwayCommons; O75376; -.
DR   Reactome; R-HSA-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-HSA-1368071; NR1D1 (REV-ERBA) represses gene expression.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-3214815; HDACs deacetylate histones.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-383280; Nuclear Receptor transcription pathway.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by PPARalpha.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-9022537; Loss of MECP2 binding ability to the NCoR/SMRT complex.
DR   Reactome; R-HSA-9022692; Regulation of MECP2 expression and activity.
DR   Reactome; R-HSA-9029569; NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux.
DR   Reactome; R-HSA-9609690; HCMV Early Events.
DR   Reactome; R-HSA-9623433; NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis.
DR   Reactome; R-HSA-9707564; Cytoprotection by HMOX1.
DR   Reactome; R-HSA-9707616; Heme signaling.
DR   SignaLink; O75376; -.
DR   SIGNOR; O75376; -.
DR   BioGRID-ORCS; 9611; 61 hits in 1216 CRISPR screens.
DR   ChiTaRS; NCOR1; human.
DR   EvolutionaryTrace; O75376; -.
DR   GeneWiki; Nuclear_receptor_co-repressor_1; -.
DR   GenomeRNAi; 9611; -.
DR   Pharos; O75376; Tchem.
DR   PRO; PR:O75376; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; O75376; protein.
DR   Bgee; ENSG00000141027; Expressed in sural nerve and 195 other tissues.
DR   ExpressionAtlas; O75376; baseline and differential.
DR   Genevisible; O75376; HS.
DR   GO; GO:0000785; C:chromatin; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0000118; C:histone deacetylase complex; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0017053; C:transcription repressor complex; IDA:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:BHF-UCL.
DR   GO; GO:0016922; F:nuclear receptor binding; IPI:UniProtKB.
DR   GO; GO:0046966; F:nuclear thyroid hormone receptor binding; IBA:GO_Central.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISS:BHF-UCL.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:BHF-UCL.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0045475; P:locomotor rhythm; ISS:UniProtKB.
DR   GO; GO:0060766; P:negative regulation of androgen receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB.
DR   GO; GO:0045922; P:negative regulation of fatty acid metabolic process; IMP:BHF-UCL.
DR   GO; GO:0045820; P:negative regulation of glycolytic process; IMP:BHF-UCL.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:1902894; P:negative regulation of miRNA transcription; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0051225; P:spindle assembly; IMP:UniProtKB.
DR   CDD; cd00167; SANT; 2.
DR   Gene3D; 1.20.5.430; -; 1.
DR   Gene3D; 1.20.58.1880; -; 1.
DR   Gene3D; 1.10.10.60; Homeodomain-like; 1.
DR   IDEAL; IID00189; -.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR017930; Myb_dom.
DR   InterPro; IPR031557; N-CoR_GPS2_interact.
DR   InterPro; IPR001005; SANT/Myb.
DR   InterPro; IPR017884; SANT_dom.
DR   PANTHER; PTHR13992; NUCLEAR RECEPTOR CO-REPRESSOR RELATED NCOR; 1.
DR   PANTHER; PTHR13992:SF5; NUCLEAR RECEPTOR COREPRESSOR 1; 1.
DR   Pfam; PF15784; GPS2_interact; 1.
DR   Pfam; PF00249; Myb_DNA-binding; 1.
DR   SMART; SM00717; SANT; 2.
DR   SUPFAM; SSF46689; Homeodomain-like; 2.
DR   PROSITE; PS51293; SANT; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Biological rhythms;
KW   Chromatin regulator; Coiled coil; DNA-binding; Isopeptide bond; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..2440
FT                   /note="Nuclear receptor corepressor 1"
FT                   /id="PRO_0000055617"
FT   DOMAIN          435..486
FT                   /note="SANT 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00624"
FT   DOMAIN          623..674
FT                   /note="SANT 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00624"
FT   REGION          1..373
FT                   /note="Interaction with ZBTB33 and HEXIM1"
FT                   /evidence="ECO:0000269|PubMed:14527417,
FT                   ECO:0000269|PubMed:17452463"
FT   REGION          1..177
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          206..231
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          254..312
FT                   /note="Interaction with SIN3A/B"
FT   REGION          497..632
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          677..915
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          988..1816
FT                   /note="Interaction with ETO"
FT   REGION          1022..1046
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1184..1204
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1440..1459
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1488..1554
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1501..2440
FT                   /note="Interaction with C1D"
FT                   /evidence="ECO:0000250"
FT   REGION          1690..1759
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1884..1922
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1943..1969
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2006..2041
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2032..2115
FT                   /note="ID1"
FT                   /evidence="ECO:0000250"
FT   REGION          2047..2050
FT                   /note="Required for interaction with RARA in the absence of
FT                   its ligand"
FT                   /evidence="ECO:0000250"
FT   REGION          2067..2155
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2212..2273
FT                   /note="ID2"
FT                   /evidence="ECO:0000250"
FT   REGION          2287..2440
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          174..216
FT                   /evidence="ECO:0000255"
FT   COILED          299..328
FT                   /evidence="ECO:0000255"
FT   COILED          501..557
FT                   /evidence="ECO:0000255"
FT   MOTIF           1933..1937
FT                   /note="CORNR box 1"
FT   MOTIF           2055..2059
FT                   /note="CORNR box 2"
FT   MOTIF           2263..2267
FT                   /note="CORNR box 3"
FT   COMPBIAS        1..39
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        47..69
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        100..115
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        162..177
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        504..570
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        605..620
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        677..698
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        712..726
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        736..795
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        823..859
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        867..884
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1488..1529
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1709..1732
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1907..1922
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1953..1967
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2020..2040
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2067..2116
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2128..2142
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2347..2361
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2371..2416
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         172
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         224
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         999
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   MOD_RES         1111
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1195
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         1196
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1249
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1263
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1281
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1322
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1336
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q60974"
FT   MOD_RES         1367
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q60974"
FT   MOD_RES         1412
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         1450
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1472
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1592
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1977
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1981
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         2102
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WUB5"
FT   MOD_RES         2120
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2136
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         2151
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         2184
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         2399
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         2436
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692"
FT   MOD_RES         2438
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   CROSSLNK        1106
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        1106
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1184
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1389
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1412
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1518
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         37..145
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_046468"
FT   VAR_SEQ         727
FT                   /note="E -> EGAENSSDTESAPSPSP (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10470851,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|Ref.2"
FT                   /id="VSP_010207"
FT   VAR_SEQ         1006..1007
FT                   /note="VL -> GR (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_046469"
FT   VAR_SEQ         1008..2440
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_046470"
FT   VAR_SEQ         1842..1961
FT                   /note="SKHEAARLEENLRSRSAAVSEQQQLEQKTLEVEKRSVQCLYTSSAFPSGKPQ
FT                   PHSSVVYSEAGKDKGPPPKSRYEEELRTRGKTTITAANFIDVIITRQIASDKDARERGS
FT                   QSSDSSSSL -> I (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10470851,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_010208"
FT   CONFLICT        5
FT                   /note="G -> V (in Ref. 2; AAO32942)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        20
FT                   /note="Y -> S (in Ref. 2; AAO32942)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        26
FT                   /note="Q -> K (in Ref. 2; AAO32942)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        31
FT                   /note="N -> S (in Ref. 2; AAO32942)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        33
FT                   /note="R -> H (in Ref. 2; AAO32942)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        392
FT                   /note="N -> S (in Ref. 2; AAO32942)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1014
FT                   /note="V -> L (in Ref. 1; AAC33550)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1508..1509
FT                   /note="SS -> PP (in Ref. 1; AAC33550)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1561
FT                   /note="R -> W (in Ref. 1; AAC33550)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1567
FT                   /note="H -> Q (in Ref. 1; AAC33550)"
FT                   /evidence="ECO:0000305"
FT   HELIX           442..454
FT                   /evidence="ECO:0007829|PDB:2EQR"
FT   HELIX           459..465
FT                   /evidence="ECO:0007829|PDB:2EQR"
FT   HELIX           471..481
FT                   /evidence="ECO:0007829|PDB:2EQR"
FT   STRAND          1343..1346
FT                   /evidence="ECO:0007829|PDB:6XYX"
FT   STRAND          1736..1740
FT                   /evidence="ECO:0007829|PDB:6XZZ"
FT   STRAND          2048..2050
FT                   /evidence="ECO:0007829|PDB:3KMZ"
FT   HELIX           2051..2063
FT                   /evidence="ECO:0007829|PDB:3KMZ"
FT   HELIX           2263..2271
FT                   /evidence="ECO:0007829|PDB:8DKV"
SQ   SEQUENCE   2440 AA;  270210 MW;  1647FE060373A125 CRC64;
     MSSSGYPPNQ GAFSTEQSRY PPHSVQYTFP NTRHQQEFAV PDYRSSHLEV SQASQLLQQQ
     QQQQLRRRPS LLSEFHPGSD RPQERRTSYE PFHPGPSPVD HDSLESKRPR LEQVSDSHFQ
     RVSAAVLPLV HPLPEGLRAS ADAKKDPAFG GKHEAPSSPI SGQPCGDDQN ASPSKLSKEE
     LIQSMDRVDR EIAKVEQQIL KLKKKQQQLE EEAAKPPEPE KPVSPPPVEQ KHRSIVQIIY
     DENRKKAEEA HKIFEGLGPK VELPLYNQPS DTKVYHENIK TNQVMRKKLI LFFKRRNHAR
     KQREQKICQR YDQLMEAWEK KVDRIENNPR RKAKESKTRE YYEKQFPEIR KQREQQERFQ
     RVGQRGAGLS ATIARSEHEI SEIIDGLSEQ ENNEKQMRQL SVIPPMMFDA EQRRVKFINM
     NGLMEDPMKV YKDRQFMNVW TDHEKEIFKD KFIQHPKNFG LIASYLERKS VPDCVLYYYL
     TKKNENYKAL VRRNYGKRRG RNQQIARPSQ EEKVEEKEED KAEKTEKKEE EKKDEEEKDE
     KEDSKENTKE KDKIDGTAEE TEEREQATPR GRKTANSQGR RKGRITRSMT NEAAAASAAA
     AAATEEPPPP LPPPPEPIST EPVETSRWTE EEMEVAKKGL VEHGRNWAAI AKMVGTKSEA
     QCKNFYFNYK RRHNLDNLLQ QHKQKTSRKP REERDVSQCE SVASTVSAQE DEDIEASNEE
     ENPEDSEVEA VKPSEDSPEN ATSRGNTEPA VELEPTTETA PSTSPSLAVP STKPAEDESV
     ETQVNDSISA ETAEQMDVDQ QEHSAEEGSV CDPPPATKAD SVDVEVRVPE NHASKVEGDN
     TKERDLDRAS EKVEPRDEDL VVAQQINAQR PEPQSDNDSS ATCSADEDVD GEPERQRMFP
     MDSKPSLLNP TGSILVSSPL KPNPLDLPQL QHRAAVIPPM VSCTPCNIPI GTPVSGYALY
     QRHIKAMHES ALLEEQRQRQ EQIDLECRSS TSPCGTSKSP NREWEVLQPA PHQVITNLPE
     GVRLPTTRPT RPPPPLIPSS KTTVASEKPS FIMGGSISQG TPGTYLTSHN QASYTQETPK
     PSVGSISLGL PRQQESAKSA TLPYIKQEEF SPRSQNSQPE GLLVRAQHEG VVRGTAGAIQ
     EGSITRGTPT SKISVESIPS LRGSITQGTP ALPQTGIPTE ALVKGSISRM PIEDSSPEKG
     REEAASKGHV IYEGKSGHIL SYDNIKNARE GTRSPRTAHE ISLKRSYESV EGNIKQGMSM
     RESPVSAPLE GLICRALPRG SPHSDLKERT VLSGSIMQGT PRATTESFED GLKYPKQIKR
     ESPPIRAFEG AITKGKPYDG ITTIKEMGRS IHEIPRQDIL TQESRKTPEV VQSTRPIIEG
     SISQGTPIKF DNNSGQSAIK HNVKSLITGP SKLSRGMPPL EIVPENIKVV ERGKYEDVKA
     GETVRSRHTS VVSSGPSVLR STLHEAPKAQ LSPGIYDDTS ARRTPVSYQN TMSRGSPMMN
     RTSDVTISSN KSTNHERKST LTPTQRESIP AKSPVPGVDP VVSHSPFDPH HRGSTAGEVY
     RSHLPTHLDP AMPFHRALDP AAAAYLFQRQ LSPTPGYPSQ YQLYAMENTR QTILNDYITS
     QQMQVNLRPD VARGLSPREQ PLGLPYPATR GIIDLTNMPP TILVPHPGGT STPPMDRITY
     IPGTQITFPP RPYNSASMSP GHPTHLAAAA SAERERERER EKERERERIA AASSDLYLRP
     GSEQPGRPGS HGYVRSPSPS VRTQETMLQQ RPSVFQGTNG TSVITPLDPT AQLRIMPLPA
     GGPSISQGLP ASRYNTAADA LAALVDAAAS APQMDVSKTK ESKHEAARLE ENLRSRSAAV
     SEQQQLEQKT LEVEKRSVQC LYTSSAFPSG KPQPHSSVVY SEAGKDKGPP PKSRYEEELR
     TRGKTTITAA NFIDVIITRQ IASDKDARER GSQSSDSSSS LSSHRYETPS DAIEVISPAS
     SPAPPQEKLQ TYQPEVVKAN QAENDPTRQY EGPLHHYRPQ QESPSPQQQL PPSSQAEGMG
     QVPRTHRLIT LADHICQIIT QDFARNQVSS QTPQQPPTST FQNSPSALVS TPVRTKTSNR
     YSPESQAQSV HHQRPGSRVS PENLVDKSRG SRPGKSPERS HVSSEPYEPI SPPQVPVVHE
     KQDSLLLLSQ RGAEPAEQRN DARSPGSISY LPSFFTKLEN TSPMVKSKKQ EIFRKLNSSG
     GGDSDMAAAQ PGTEIFNLPA VTTSGSVSSR GHSFADPASN LGLEDIIRKA LMGSFDDKVE
     DHGVVMSQPM GVVPGTANTS VVTSGETRRE EGDPSPHSGG VCKPKLISKS NSRKSKSPIP
     GQGYLGTERP SSVSSVHSEG DYHRQTPGWA WEDRPSSTGS TQFPYNPLTM RMLSSTPPTP
     IACAPSAVNQ AAPHQQNRIW EREPAPLLSA QYETLSDSDD
//
